GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

AT2221

Company
Amicus Therapeutics
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for AT2221 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT04808505

    A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18

    Not yet reported Amicus Therapeutics 36 participants Est. completion 2027-07 14 sites
    Other conditions: Glycogen Storage Disease Type II Infantile Onset
    View official trial listing →
  • Recruiting NCT NCT06121011

    A Global Prospective Observational Registry of Patients With Pompe Disease

    Amicus Therapeutics 500 participants Est. completion 2034-12-20 41 sites
    Other conditions: Pompe Disease
    View official trial listing →
  • Completed NCT NCT02675465

    First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

    Not yet reported, Not yet reported Amicus Therapeutics 29 participants Est. completion 2024-08-22 19 sites Stand-alone
    Other conditions: Pompe Disease
    View official trial listing →
  • Completed NCT NCT03729362

    A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease

    Not yet reported Amicus Therapeutics 125 participants Est. completion 2021-01-15 73 sites
    Other conditions: Pompe Disease (Late-onset)
    View official trial listing →
  • Available NCT NCT03865836

    Expanded Access for ATB200/AT2221 for the Treatment of Pompe Disease

    Amicus Therapeutics
    Other conditions: Pompe Disease
    View official trial listing →
  • Active, not recruiting NCT NCT03911505

    ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

    Not yet reported Amicus Therapeutics 21 participants Est. completion 2026-06 17 sites Stand-alone
    Other conditions: Pompe Disease (Late-onset)
    View official trial listing →
  • Completed NCT NCT04138277

    A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

    Not yet reported Amicus Therapeutics 119 participants Est. completion 2024-12-31 60 sites Stand-alone
    Other conditions: Pompe Disease (Late-onset)
    View official trial listing →
  • Available NCT NCT04327973

    Expanded Access for ATB200/AT2221 for the Treatment of IOPD

    Amicus Therapeutics 4 sites
    Other conditions: Pompe Disease Infantile-Onset
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.